How many insider trades does FilingIQ track for SPRY?

FilingIQ tracks 334 Form 4 insider transactions for SPRY (ARS Pharmaceuticals, Inc.), covering filings from Nov 10, 2022 onwards. 0 of those are dated within the last 90 days.

Are SPRY insiders net buyers or net sellers?

Across the full Form 4 history for SPRY, 11 transactions (3%) were open-market purchases and 223 (67%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does SPRY insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is SPRY in?

ARS Pharmaceuticals, Inc. (SPRY) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $774.57M.

SPRY insider trading

NasdaqGM Healthcare

ARS Pharmaceuticals, Inc.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

334

Last 90 days

Buys / sells

3% / 67%

Market cap

$774.57M

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Company website: ars-pharma.com

SPRY insider activity at a glance

FilingIQ tracks 334 insider transactions for SPRY in filings since Nov 10, 2022. The most recent transaction is dated Jun 12, 2026.

Across the full history, 11 open-market purchases and 223 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on SPRY insider trades is 66.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live SPRY trades on FilingIQ Raw filings on SEC EDGAR

Latest SPRY Form 4 filings

Casale Donn President and CEO

A Oct 5, 2026

Smith Margaret Ekins Chief Commercial Officer

A Sep 2, 2026

Casale Donn President

RA CAPITAL MANAGEMENT, L.P.

A Jun 26, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 820

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

CORT 110

CORCEPT THERAPEUTICS INC

TEM 104

Tempus AI, Inc.

Frequently asked

How many insider trades does FilingIQ track for SPRY?: FilingIQ tracks 334 Form 4 insider transactions for SPRY (ARS Pharmaceuticals, Inc.), covering filings from Nov 10, 2022 onwards. 0 of those are dated within the last 90 days.
Are SPRY insiders net buyers or net sellers?: Across the full Form 4 history for SPRY, 11 transactions (3%) were open-market purchases and 223 (67%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does SPRY insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is SPRY in?: ARS Pharmaceuticals, Inc. (SPRY) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $774.57M.

Methodology & sources

Every SPRY insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.